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Reply to the Editor:
We thank Pocar and colleagues for their
interest in our article regarding surgery for
acute type A aortic dissection in the setting
of stroke.1 We also acknowledge their re-
cent report about repairing acute type A
aortic dissection in patients with coma.2 As
was pointed out in their report, the use of
the Glasgow Coma Scale (GCS) to exclude
patients for type A aortic repair was not
relevant. Specifically, they noted that all 5
of their patients would have been consid-
ered severely brain injured (GCS  8)
based on the GCS alone. We do appreciate
and concur with this point and also con-
gratulate them for them for their results in
this very difficult subgroup of patients.
Although the GCS, the National Insti-
tutes of Health Stroke Scale (NIHSS), and
Rankin score for that matter may not be
completely applicable in the setting of
acute type A aortic dissection, we wanted
to analyze these patients with objective cri-
teria. We do believe that the NIHSS and the
Rankin score may be helpful, although this
study was not powered to demonstrate this.
Because we recommended that operative
repair was indicated in patients without
“neurologic devastation” or coma, we at-
tempted to provide some objective criteria
for this condition, hence the use of these
scales and scores. Regarding the 1 nonop-
erated patient who was considered neuro-
logically devastated, we acknowledge that
one cannot derive any conclusions in rela-
tion to defining neurologic devastation. In
fact, it was the appearance of the patient’s
computed tomography scan of the head,
which showed bilateral massive infarction,
that ultimately led to his nonoperative
course.
Prior to the results of this study, we
maintained that stroke was a relative con-
traindication to immediate repair for acute
type A aortic dissection. We have since
modified our approach and have become
more aggressive in repairing acute type A
aortic dissection in patients with stroke.
Our experience in patients with coma,
however, has been limited and thus we
continue to maintain a selective approach
in patients with coma and neurologic dev-
astation. We admit that GCS is not a good
measure of coma or neurologic devasta-
tion, and radiographic evaluation, in the
hemodynamically stable patient, may be
more helpful. How coma and neurologic
devastation are determined and whether or
not surgery is performed, however, should
be left ultimately to the neurologist and
operating surgeon, respectively.
Anthony L. Estrera, MD
Hazim J. Safi, MD
University of Texas Medical School
Houston, TX
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High-dose atorvastatin is associated
with impaired myocardial
angiogenesis in response to vascular
endothelial growth factor in
hypercholesterolemic swine:
Relevance to the human situation?
To the Editor:
We read with great interest the article by
Boodhwani and colleagues1 regarding the
impact of high-dose statin therapy on vas-
cular endothelial growth factor-A (VEGF-
A)–induced myocardial angiogenesis in a
hypercholesterolemic pig model of chronic
ischemia. This article demonstrated that
collateral-dependent myocardial perfusion
remained impaired in hypercholesterolemic
and atorvastatin-treated pigs in response to
additional treatment with VEGF-A relative
to a normocholesterolemic control group.
It concluded that a high-dose statin therapy
was not associated with improved myocar-
dial neovascularization. In that study,
however, the hypercholesterolemic pigs
were treated with an atorvastatin dosage
of 3 mg/(kg · d), which exceeds the
maximal possible dosage in patients (80
mg/d) by a factor of about 3.
To achieve at least moderate choles-
terol lowering, pigs need to be treated
with high-dose statins because of lesser
lipid-lowering potency and efficacy in
pigs relative to human beings.2 One must
remain aware, however, of the increased
risk of adverse events with extremely
high statin dosages. In their article,
Boodhwani and colleagues1 described a
clearly decreased capillary endothelial cell
density in the ischemic territory in the hyper-
cholesterolemic and atorvastatin-treated pigs
relative to the normocholesterolemic pigs and
even the untreated hypercholesterolemic an-
imals. To exclude the possibility that the hy-
percholesterolemic and atorvastatin-treated
pigs suffered potential toxic (cellular) side
effects of atorvastatin that might explain the
neovascularization impairment, the investi-
gators should have incorporated a control
group of normocholesterolemic pigs treated
with the same atorvastatin dosage. Moreover,
treatment of the hypercholesterolemic pigs
with lower atorvastatin dosages, more rel-
evant to the human situation, might dem-
onstrate whether there are potential dose-
dependent toxic cellular side effects.
Indeed, a recently published article by
Chade and associates3 indicates that statins
used in an intermediate (human) dosage in
pigs do lead to a stimulation of arteriogen-
esis. Furthermore, a retrospective clinical
study supports the view that intensified statin
treatment is associated with an improved arte-
riogenic response in human beings.4
Another piece of evidence for statin
overdose in the hypercholesterolemic pigs
of Boodhwani and colleagues1 might be the
observation of prolonged Akt activation in
the atorvastatin-treated pigs. Therefore, the
Akt downstream signal transduction path-
ways in endothelial cells might not any
longer be able to respond adequately to
other pathophysiologic stimuli. Indeed, it
has been demonstrated that a prolonged Akt
activation is associated with detrimental
cardiac effects in an ischemic mouse
model,5 as was even cited by Boodhwani
and colleagues1 in their article.
Taken together, we believe that it is not
appropriate to compare directly the arterio-
genic effects of high-dose statin treatment
in pigs and human beings in light of the
approximately 3-fold higher statin dosage
used in pigs.
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